Drug interactions
Sorafenib + Umeclidinium-vilanterol
Severity: Moderate
Sorafenib and Umeclidinium-vilanterol: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Sorafenib can prolong the QT interval, and vilanterol may add adrenergic cardiac effects and lower potassium. The combination may raise arrhythmia risk in susceptible patients.
What this interaction means in plain words
Sorafenib and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Sorafenib belongs to Oncology; Umeclidinium-vilanterol belongs to Respiratory.
Why it happens
Additive effects on cardiac repolarization and adrenergic stimulation.
What to do
Monitor ECG and electrolytes in patients with other QT risk factors, and correct any abnormalities.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Sorafenib and Umeclidinium-vilanterol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Umeclidinium-vilanterol
Other interactions of Sorafenib
Frequently asked questions
Can I take Sorafenib with Umeclidinium-vilanterol?
MediHelp rates the interaction as moderate. Sorafenib and Umeclidinium-vilanterol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Sorafenib can prolong the QT interval, and vilanterol may add adrenergic cardiac effects and lower potassium. The combination may raise arrhythmia risk in susceptible patients.
How serious is the interaction between Sorafenib and Umeclidinium-vilanterol?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes in patients with other QT risk factors, and correct any abnormalities.
What other medicines interact with Umeclidinium-vilanterol?
MediHelp also lists interactions of Umeclidinium-vilanterol with, for example, Aclidinium, Amiodarone, Amitriptyline. The full list is on the Umeclidinium-vilanterol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
